Literature DB >> 16175600

Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling.

Suk Woo Nam1, Jik Young Park, Adaikalavan Ramasamy, Shirish Shevade, Amirul Islam, Philip M Long, Cheol Keun Park, Soo Eun Park, Su Young Kim, Sug Hyung Lee, Won Sang Park, Nam Jin Yoo, Edison T Liu, Lance D Miller, Jung Young Lee.   

Abstract

Progression of hepatocellular carcinoma (HCC) is a stepwise process that proceeds from pre-neoplastic lesions--including low-grade dysplastic nodules (LGDNs) and high-grade dysplastic nodules (HGDNs)--to advanced HCC. The molecular changes associated with this progression are unclear, however, and the morphological cues thought to distinguish pre-neoplastic lesions from well-differentiated HCC are not universally accepted. To understand the multistep process of hepato-carcinogenesis at the molecular level, we used oligo-nucleotide microarrays to investigate the transcription profiles of 50 hepatocellular nodular lesions ranging from LGDNs to primary HCC (Edmondson grades 1-3). We demonstrated that gene expression profiles can discriminate not only between dysplastic nodules and overt carcinoma but also between different histological grades of HCC via unsupervised hierarchical clustering with 10,376 genes. We identified 3,084 grade-associated genes, correlated with tumor progression, using one-way ANOVA and a one-versus-all unpooled t test. Functional assignment of these genes revealed discrete expression clusters representing grade-dependent biological properties of HCC. Using both diagonal linear discriminant analysis and support vector machines, we identified 240 genes that could accurately classify tumors according to histological grade, especially when attempting to discriminate LGDNs, HGDNs, and grade 1 HCC. In conclusion, a clear molecular demarcation between dysplastic nodules and overt HCC exists. The progression from grade 1 through grade 3 HCC is associated with changes in gene expression consistent with plausible functional consequences.

Entities:  

Mesh:

Year:  2005        PMID: 16175600     DOI: 10.1002/hep.20878

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  53 in total

Review 1.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

2.  Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas.

Authors:  Jian-Hua Luo; Baoguo Ren; Sergei Keryanov; George C Tseng; Uma N M Rao; Satdarshan P Monga; Steven Strom; Anthony J Demetris; Michael Nalesnik; Yan P Yu; Sarangarajan Ranganathan; George K Michalopoulos
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

Review 3.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

4.  A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma.

Authors:  Paul C Schröder; Víctor Segura; José Ignacio Riezu; Bruno Sangro; José M Mato; Jesús Prieto; Enrique Santamaría; Fernando J Corrales
Journal:  Funct Integr Genomics       Date:  2011-05-12       Impact factor: 3.410

5.  Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.

Authors:  Seong Jin Hwang; Min Jung Suh; Joo Hee Yoon; Mee Ran Kim; Ki Sung Ryu; Suk Woo Nam; Patricia K Donahoe; David T Maclaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2011-05-13       Impact factor: 5.650

6.  An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis.

Authors:  Maddalena Frau; Maria M Simile; Maria L Tomasi; Maria I Demartis; Lucia Daino; Maria A Seddaiu; Stefania Brozzetti; Claudio F Feo; Giovanni Massarelli; Giuliana Solinas; Francesco Feo; Ju-Seog Lee; Rosa M Pascale
Journal:  Cell Oncol (Dordr)       Date:  2012-03-21       Impact factor: 6.730

Review 7.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

Authors:  Augusto Villanueva; Beatriz Minguez; Alejandro Forner; Maria Reig; Josep M Llovet
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 8.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old.

Authors:  Dilek Colak; Muhammad A Chishti; Al-Bandary Al-Bakheet; Ahmed Al-Qahtani; Mohamed M Shoukri; Malcolm H Goyns; Pinar T Ozand; John Quackenbush; Ben H Park; Namik Kaya
Journal:  Mol Cancer       Date:  2010-06-12       Impact factor: 27.401

10.  Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.

Authors:  Pal Kaposi-Novak; Louis Libbrecht; Hyun Goo Woo; Yun-Han Lee; Nathaniel C Sears; Cedric Coulouarn; Elizabeth A Conner; Valentina M Factor; Tania Roskams; Snorri S Thorgeirsson
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.